Albendazole
Albenza (albendazole) is a small molecule pharmaceutical. Albendazole was first approved as Albenza on 1996-06-11. It is used to treat ancylostomiasis, clonorchiasis, echinococcosis, enterobiasis, and giardiasis amongst others in the USA.
Download report
Favorite
Searched
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Albendazole
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ALBENZA | Impax Laboratories | N-020666 DISCN | 1996-06-11 | 1 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| albendazole | ANDA | 2023-03-16 |
| albenza | New Drug Application | 2019-06-19 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| ancylostomiasis | EFO_0007145 | D000724 | B76.0 |
| clonorchiasis | EFO_0007210 | D003003 | B66.1 |
| echinococcosis | EFO_0007245 | D004443 | B67 |
| enterobiasis | — | D017229 | B80 |
| giardiasis | DOID_10718 | D005873 | A07.1 |
| helminthiasis | EFO_1001342 | D006373 | B65-B83 |
| hymenolepiasis | EFO_0007317 | D006925 | B71.0 |
| necatoriasis | EFO_0007390 | D009332 | B76.1 |
| neurocysticercosis | — | D020019 | — |
| opisthorchiasis | EFO_0007404 | D009889 | B66.0 |
Show 2 more
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
104 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Helminthiasis | D006373 | EFO_1001342 | B65-B83 | 2 | 3 | 2 | 4 | 9 | 19 |
| Filarial elephantiasis | D004605 | EFO_0007272 | B74.0 | — | 6 | 3 | 4 | 5 | 17 |
| Trichuriasis | D014257 | EFO_0007524 | B79 | — | 7 | 3 | 2 | 1 | 11 |
| Infections | D007239 | EFO_0000544 | — | 2 | 2 | 2 | 3 | 7 | |
| Hookworm infections | D006725 | EFO_0007314 | B76 | — | 4 | 2 | 1 | 1 | 7 |
| Anemia | D000740 | EFO_0004272 | D64.9 | — | 1 | 1 | 3 | 3 | 7 |
| Malaria | D008288 | EFO_0001068 | B54 | — | 1 | 2 | 1 | 3 | 6 |
| Ascariasis | D001196 | EFO_0007154 | B77 | — | 1 | 2 | 1 | 2 | 5 |
| Trachoma | D014141 | A71 | — | — | 1 | 2 | — | 3 | |
| Schistosomiasis | D012552 | EFO_1001475 | B65 | — | — | — | 1 | 1 | 2 |
Show 6 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neurocysticercosis | D020019 | — | 2 | 5 | — | — | 6 | ||
| Malnutrition | D044342 | EFO_0008572 | E40-E46 | — | — | 2 | — | 3 | 5 |
| Onchocerciasis | D009855 | EFO_0007402 | B73 | — | 1 | 2 | — | 2 | 5 |
| Hiv infections | D015658 | EFO_0000764 | B20 | — | — | 1 | — | 3 | 4 |
| Strongyloidiasis | D013322 | EFO_0007501 | B78 | — | — | 2 | — | 1 | 3 |
| Yaws | D015001 | EFO_0007548 | A66 | — | 1 | 1 | — | — | 2 |
| Epilepsy | D004827 | EFO_0000474 | G40.9 | — | 1 | 1 | — | 1 | 2 |
| Scabies | D012532 | B86 | — | — | 1 | — | — | 1 | |
| Hiv | D006678 | O98.7 | — | — | 1 | — | — | 1 | |
| Filariasis | D005368 | B74 | — | — | 1 | — | — | 1 |
Show 5 more
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Parasitic diseases | D010272 | EFO_0001067 | B88 | — | — | — | — | 4 | 4 |
| Abdominal pain | D015746 | R10.9 | — | — | — | — | 2 | 2 | |
| Growth disorders | D006130 | — | — | — | — | 1 | 1 | ||
| Nutrition disorders | D009748 | EFO_0001069 | — | — | — | — | 1 | 1 | |
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | — | — | — | — | 1 | 1 |
| Bacterial infections | D001424 | A49 | — | — | — | — | 1 | 1 | |
| Cysticercosis | D003551 | EFO_0007231 | B69 | — | — | — | — | 1 | 1 |
| Pruritus | D011537 | HP_0000989 | L29 | — | — | — | — | 1 | 1 |
| Lymphedema | D008209 | Q82.0 | — | — | — | — | 1 | 1 | |
| Mansonelliasis | D008368 | EFO_0007357 | B74.4 | — | — | — | — | 1 | 1 |
Show 11 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | ALBENDAZOLE |
| INN | albendazole |
| Description | Albendazole is a carbamate ester that is methyl 1H-benzimidazol-2-ylcarbamate substituted by a propylsulfanyl group at position 5. It is commonly used in the treatment of parasitic worm infestations. It has a role as a tubulin modulator, a microtubule-destabilising agent and an anthelminthic drug. It is a carbamate ester, a benzimidazolylcarbamate fungicide, an aryl sulfide and a member of benzimidazoles. |
| Classification | Small molecule |
| Drug class | antithelmintics (tibendazole type) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CCCSc1ccc2[nH]c(NC(=O)OC)nc2c1 |
Identifiers
| PDB | — |
| CAS-ID | 54965-21-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1483 |
| ChEBI ID | 16664 |
| PubChem CID | 2082 |
| DrugBank | DB00518 |
| UNII ID | F4216019LN (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 12,143 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
44 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more